Disease · MONDO_0005393

gout

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. gout. Diseases, record MONDO_0005393. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005393

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: gout; Open Targets
Open Targets ID: MONDO_0005393; Open Targets
Other names: Gouty arthritis, gouty arthropathy; Open Targets
Disease Ontology: DOID:13189; Disease Ontology
MeSH: D006073; MeSH
NCI Thesaurus: C34650; NCI Thesaurus
Highest stage of its drugs: Approval, for 25 of its 62 drugs, from ATC, DailyMed, EMA Human Drugs, FDA, PMDA and TTD; Open Targets

Drugs62

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
FEBUXOSTAT	CHEMBL1164729	Small molecule	Approval	ATC, EMA Human Drugs and PMDA	49	44	44	Drugs and targets
ALLOPURINOL	CHEMBL1467	Small molecule	Approval	ATC and DailyMed	83	32	32	Drugs and targets
PEGLOTICASE	CHEMBL1237025	Enzyme	Approval	ATC, DailyMed and TTD	17	12	11	Drugs and targets
DOTINURAD	CHEMBL4594446	Small molecule	Approval	PMDA	12	10	10	Drugs and targets
LESINURAD	CHEMBL2105720	Small molecule	Approval	ATC	9	7	7	Drugs and targets
CANAKINUMAB	CHEMBL1201834	Antibody	Approval	EMA Human Drugs	8	7	7	Drugs and targets
COLCHICINE	CHEMBL107	Small molecule	Approval	ATC and DailyMed	21	6	6	Drugs and targets
NAPROXEN	CHEMBL154	Small molecule	Approval	DailyMed	124	2	1	Drugs and targets
INDOMETHACIN	CHEMBL6	Small molecule	Approval	DailyMed	78	2	2	Drugs and targets
BENZBROMARONE	CHEMBL388590	Small molecule	Approval	ATC and TTD	4	2	2	Drugs and targets

1 to 10 of 62

See all 62 drugs

Targets94

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PTGS2	Cyclooxygenase	9	Cyclooxygenase inhibitor; Cyclooxygenase-2 inhibitor	Approval	https://conductscience.org/library/genes/5743	Drugs and targets
NR3C1	Glucocorticoid receptor	8	Glucocorticoid receptor agonist	Approval	https://conductscience.org/library/genes/2908	Drugs and targets
PTGS1	Cyclooxygenase	7	Cyclooxygenase inhibitor	Approval	https://conductscience.org/library/genes/5742	Drugs and targets
SLC22A12	Solute carrier family 22 member 12	7	Solute carrier family 22 member 12 inhibitor	Approval	https://conductscience.org/library/genes/116085	Drugs and targets
XDH	Xanthine dehydrogenase/oxidase	3	Xanthine dehydrogenase inhibitor	Approval	https://conductscience.org/library/genes/7498	Drugs and targets
IL1B	Interleukin-1 beta	2	Interleukin-1 beta inhibitor	Approval	https://conductscience.org/library/genes/3553	Drugs and targets
PPARG	Peroxisome proliferator-activated receptor gamma	2	Peroxisome proliferator-activated receptor gamma agonist; Peroxisome proliferator-activated receptor gamma modulator	Phase 2/3	https://conductscience.org/library/genes/5468	Drugs and targets
ALOX5	Polyunsaturated fatty acid 5-lipoxygenase	1	Arachidonate 5-lipoxygenase inhibitor	Early phase 1	https://conductscience.org/library/genes/240	Drugs and targets
COXFA4	Mitochondrial complex I (NADH dehydrogenase)	1	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Phase 2	https://conductscience.org/library/genes/4697	Drugs and targets
COXFA4L2	Mitochondrial complex I (NADH dehydrogenase)	1	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Phase 2	https://conductscience.org/library/genes/56901	Drugs and targets

1 to 10 of 94

See all 94 targets

Trials132

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00430248	Efficacy and Safety of Oral Febuxostat in Participants With Gout	Phase 3	2,269	2009-07-16	Gout	FEBUXOSTAT	Its record names the disease	ClinicalTrials.gov
NCT02139046	Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout	Phase 3	1,790	2016-11-03	Gout	FEBUXOSTAT	Its record names the disease	ClinicalTrials.gov
NCT01391325	Allopurinol Outcome Study	Phase 4	1,735	2014-06-17	Gout	ALLOPURINOL	Its record names the disease	ClinicalTrials.gov
NCT00175019	Allopurinol Versus Febuxostat in Subjects Completing the Phase 3 Trials C02-009 or C02-010	Phase 3	1,086	2009-09-07	Gout	ALLOPURINOL, FEBUXOSTAT	Its record names the disease	ClinicalTrials.gov
NCT00174915	Phase 3, Febuxostat, Allopurinol and Placebo-Controlled Study in Gout Subjects.	Phase 3	1,072	2009-07-16	Gout	ALLOPURINOL, FEBUXOSTAT	Its record names the disease	ClinicalTrials.gov
NCT00102440	Febuxostat Versus Allopurinol Control Trial in Subjects With Gout	Phase 3	760	2009-07-16	Gout	ALLOPURINOL, FEBUXOSTAT	Its record names the disease	ClinicalTrials.gov
NCT01493531	Combining Lesinurad With Allopurinol in Inadequate Responders	Phase 3	610	2016-05-26	Gout	ALLOPURINOL, LESINURAD	Its record names the disease	ClinicalTrials.gov
NCT01510158	Combining Lesinurad With Allopurinol in Inadequate Responders	Phase 3	607	2016-08-18	Gout	ALLOPURINOL, LESINURAD	Its record names the disease	ClinicalTrials.gov
NCT02082769	Safety and Efficacy of Oral Febuxostat in Subjects With Gout	Phase 3	504	2016-02-03	Gout	ALLOPURINOL, FEBUXOSTAT	Its record names the disease	ClinicalTrials.gov
NCT05007392	A Study to Evaluate Efficacy of Dotinurad and Febuxostat for the Treatment of Participants With Gout	Phase 3	451	2025-07-30	Gout	DOTINURAD, FEBUXOSTAT	Its record names the disease	ClinicalTrials.gov

1 to 10 of 132

See all 132 trials

Comparisons in its trials27

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Febuxostat vs Dotinurad: deaths from any cause	0 of 225	0 of 223	448	NCT05007392	Trial comparisons
Febuxostat vs Dotinurad: serious adverse events	4 of 225	3 of 223	448	NCT05007392	Trial comparisons
Low-dose Colchicine vs Naproxen: deaths from any cause	0 of 199	0 of 200	399	NCT01994226	Trial comparisons
Low-dose Colchicine vs Naproxen: serious adverse events	1 of 199	2 of 200	399	NCT01994226	Trial comparisons
Febuxostat 40 mg or 80 mg vs Placebo: serious adverse events	13 of 157	11 of 157	314	NCT01078389	Trial comparisons
Lesinurad 400 mg vs Placebo: serious adverse events	9 of 107	4 of 107	214	NCT01508702	Trial comparisons
Lesinurad 200 mg + Febuxostat 80 mg vs Lesinurad 400 mg + Febuxostat 80 mg: deaths from any cause	1 of 97	0 of 99	196	NCT01808144	Trial comparisons
Lesinurad 200 mg + Febuxostat 80 mg vs Lesinurad 400 mg + Febuxostat 80 mg: serious adverse events	16 of 97	19 of 99	196	NCT01808144	Trial comparisons
Febuxostat 80/120 mg/Day vs Allopurinol 100 up to 600 mg/Day: deaths from any cause	0 of 98	0 of 98	196	NCT02500641	Trial comparisons
Febuxostat 80/120 mg/Day vs Allopurinol 100 up to 600 mg/Day: serious adverse events	10 of 98	8 of 98	196	NCT02500641	Trial comparisons

1 to 10 of 27

See all 27 comparisons in its trials

Papers from its trials85

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
39835962	RESULT	1	PubMed
39300602	RESULT	1	PubMed
38468241	RESULT	1	PubMed
37993515	RESULT	1	PubMed
36388084	RESULT	1	PubMed
35342538	RESULT	1	PubMed
34907116	RESULT	1	PubMed
33399399	RESULT	1	PubMed
31870173	RESULT	1	PubMed
30085130	RESULT	1	PubMed

1 to 10 of 85

See all 85 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005393

GET https://conductscience.org/api/diseases/v1/MONDO_0005393/drugs?page=2

API reference For AI assistants